CCR8 and neoplasm: Anti-CCR8 monoclonal antibodies and anti-CCR8 antibody with Fc-dependent ADCC (antibody dependent cellular cytotoxicity) selectively depletes tumour-infiltrating Treg cells due to significantly increased CCR8 expression by the activated Treg cells in TME, resulting in a durable anti-tumour immune response without deleterious autoimmunity and the anti-tumour effects can be synergized with PD-1 blockers (47, 49, 50).